Michael Wiederhorn
Stock Analyst at Oppenheimer
(4.71)
# 706
Out of 4,362 analysts
1155
Total ratings
58.3%
Success rate
10.2%
Average return
Main Sectors:
Stocks Rated by Michael Wiederhorn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PACS PACS Group | Rated: Buy | $42 → $48 | $36.91 | +30.05% | 5 | May 13, 2026 | |
| PNTG The Pennant Group | Maintained: Buy | $40 | $30.86 | +29.62% | 18 | May 8, 2026 | |
| GRDN Guardian Pharmacy Services | Maintained: Buy | $43 | $38.92 | +10.48% | 7 | May 7, 2026 | |
| ADUS Addus HomeCare | Rated: Buy | $155 | $90.45 | +71.37% | 113 | May 6, 2026 | |
| HUM Humana | Maintained: Buy | $250 → $260 | $320.88 | -18.97% | 79 | Apr 30, 2026 | |
| CNC Centene | Rated: Buy | $45 → $58 | $59.99 | -3.32% | 163 | Apr 29, 2026 | |
| HCA HCA Healthcare | Rated: Buy | $520 | $367.35 | +41.55% | 95 | Apr 27, 2026 | |
| CYH Community Health Systems | Maintained: Buy | $4 | $2.78 | +43.88% | 120 | Apr 23, 2026 | |
| UNH UnitedHealth Group | Rated: Buy | $385 → $405 | $377.92 | +7.17% | 87 | Apr 22, 2026 | |
| CHE Chemed | Maintained: Buy | $500 | $417.21 | +19.84% | 117 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $165.58 | - | 86 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.96 | - | 12 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 → $7 | $7.54 | -7.16% | 30 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $13.09 | - | 71 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $365 | $272.72 | +33.84% | 74 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $89.50 | n/a | 17 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 | $0.0001 | n/a | 6 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $44.49 | n/a | 1 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $389.03 | n/a | 48 | Jun 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $7 | $0.0001 | n/a | 6 | Aug 19, 2014 |
PACS Group
May 13, 2026
Rated: Buy
Price Target: $42 → $48
Current: $36.91
Upside: +30.05%
The Pennant Group
May 8, 2026
Maintained: Buy
Price Target: $40
Current: $30.86
Upside: +29.62%
Guardian Pharmacy Services
May 7, 2026
Maintained: Buy
Price Target: $43
Current: $38.92
Upside: +10.48%
Addus HomeCare
May 6, 2026
Rated: Buy
Price Target: $155
Current: $90.45
Upside: +71.37%
Humana
Apr 30, 2026
Maintained: Buy
Price Target: $250 → $260
Current: $320.88
Upside: -18.97%
Centene
Apr 29, 2026
Rated: Buy
Price Target: $45 → $58
Current: $59.99
Upside: -3.32%
HCA Healthcare
Apr 27, 2026
Rated: Buy
Price Target: $520
Current: $367.35
Upside: +41.55%
Community Health Systems
Apr 23, 2026
Maintained: Buy
Price Target: $4
Current: $2.78
Upside: +43.88%
UnitedHealth Group
Apr 22, 2026
Rated: Buy
Price Target: $385 → $405
Current: $377.92
Upside: +7.17%
Chemed
Mar 31, 2026
Maintained: Buy
Price Target: $500
Current: $417.21
Upside: +19.84%
Mar 20, 2026
Maintained: Buy
Price Target: n/a
Current: $165.58
Upside: -
Mar 20, 2026
Maintained: Buy
Price Target: n/a
Current: $3.96
Upside: -
Mar 3, 2026
Maintained: Buy
Price Target: $12 → $7
Current: $7.54
Upside: -7.16%
Nov 19, 2025
Maintained: Hold
Price Target: n/a
Current: $13.09
Upside: -
Oct 31, 2025
Maintained: Buy
Price Target: $365
Current: $272.72
Upside: +33.84%
Aug 9, 2024
Maintained: Hold
Price Target: n/a
Current: $89.50
Upside: n/a
Mar 2, 2023
Maintained: Buy
Price Target: $3
Current: $0.0001
Upside: n/a
Feb 9, 2018
Reiterated: Buy
Price Target: $35
Current: $44.49
Upside: n/a
Jun 7, 2017
Rated: Hold
Price Target: n/a
Current: $389.03
Upside: n/a
Aug 19, 2014
Rated: Buy
Price Target: $7
Current: $0.0001
Upside: n/a